Beauveria keratitis and biopesticides: Case histories and a random amplification of polymorphic DNA comparison

Cornea

Volumn 29, Issue 2, 2010, Pages 152-158

  Pariseau, Brett ^a   Nehls, Sarah ^b   Ogawa, Gregory S H ^c   Sutton, Deanna A ^d   Wickes, Brian L ^d   Romanelli, Anna M ^d  

^a Monroe Clinic   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c Eye Associates of New Mexico   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Beauveria; Biopesticide; Keratitis; Voriconazole

Indexed keywords

AMPHOTERICIN; ATROPINE; CEFAZOLIN; CHLORAMPHENICOL; COTRIMOXAZOLE; DEXAMETHASONE; DEXAMETHASONE PLUS TOBRAMYCIN; FLUCONAZOLE; GENTAMICIN; HOMATROPINE; HYDROCORTISONE; KETOCONAZOLE; KETOROLAC TROMETAMOL; MICONAZOLE; MOXIFLOXACIN; MYDRIATIC AGENT; NATAMYCIN; PESTICIDE; POLYMYXIN; POLYSPORIN; POSACONAZOLE; PREDNISOLONE; PREDNISOLONE ACETATE; SCOPOLAMINE; TOBRAMYCIN; TRIFLURIDINE; TROMETAMOL; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE;

ADULT; ARTICLE; BEAUVERIA; BEAUVERIA KERATITIS; BEDTIME DOSAGE; CASE REPORT; CATARACT EXTRACTION; CONTACT LENS; CONTROLLED STUDY; CORNEA ULCER; DISEASE COURSE; DNA SEQUENCE; DRUG WITHDRAWAL; EYE IRRITATION; EYE PAIN; FEMALE; FUNGUS ISOLATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KERATITIS; LIVER FUNCTION TEST; PENETRATING KERATOPLASTY; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOM AMPLIFIED POLYMORPHIC DNA; SIDE EFFECT; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNITED STATES; VISUAL ACUITY;

ADULT; ANTIFUNGAL AGENTS; BEAUVERIA; CONTACT LENSES, HYDROPHILIC; CORNEAL ULCER; DNA, FUNGAL; DRUG THERAPY, COMBINATION; EYE INFECTIONS, FUNGAL; FEMALE; HUMANS; MIDDLE AGED; MYCOSES; PEST CONTROL; PYRIMIDINES; RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE; TRIAZOLES;

EID: 77649097148     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181ae2575     Document Type: Article

References (36)

1. Madsen AM, Hansen VM, Meyling NV, et al. Human exposure to airborne fungi from genera used as biocontrol agents in plant production. Ann Agric Environ Med. 2007;14:5-24.
2. Bassi A. Del male del segno calcinaccio o muscordino malattia che attigee: Bachi da set a Patel. Teorica Tip. Orcesi, Lodi, 1835. In: Rippon JW, ed. Medical Mycology-The Pathogenic Fungi and the Pathogenic Actinomycetes. Philadelphia, PA: WB Saunders; 1974:467.
3. New fungal strains spells trouble for caterpillar pests. Agricultural Research Magazine. United States Department of Agriculture, Agricultural Research Service; 2008. Available at: http://www.ars.usda.gov/is/ AR/archive/nov00/pests1100.htm. Accessed July 8, 2009.
4. B. bassiana strain GHA (128924) fact sheet. United States Environmental Protection Agency. Available at: http://www.epa.gov/pesticides/biopesticides/ ingredients/factsheets/factsheet-128924.htm. Accessed July 8, 2009.
5. Tu EY, Park AJ. Recalcitrant B. bassiana keratitis: confocal microscopy findings and treatment with posaconazole (Noxafil). Cornea. 2007;8: 1008-1010.
6. McDonnell PJ, Werblin TP, Sigler L, et al. Mycotic keratitis due to Beauveria alba. Cornea. 1984-1985;3:213-216.
7. Ishibashi Y, Matsumoto Y, Takei K. The effects of intravenous miconazole on fungal keratitis. Am J Ophthalmol. 1984;98:433-437.
8. Sachs SW, Baum J, Mies C. B. bassiana keratitis. Br J Ophthalmol. 1985; 69:548-550.
9. Low CD, Badenoch PR, Coster DJ. B. bassiana keratitis cured by deep lamellar dissection. Cornea. 1997;16:698-699.
10. Kisla TA, Cu-Unjieng A, Sigler L, et al. Medical management of B. bassiana keratitis. Cornea. 2000;19:405-406.
11. Biopesticide active ingredient fact sheets A, B. United States Environmental Protection Agency. Available at: http://www.epa.gov/pesticides/ biopesticides/ingredients/index-ab.htm#b. Accessed July 8, 2009.
12. Laverlam International Corporation.Available at: http://www.laverla mintl.com/. Accessed July 8, 2009.
13. Troy Biosciences, Inc. Available at: http://www.troybiosciences.com/. Accessed July 8, 2009.
14. Biopesticide registration action document, B. bassiana HF23 (PC code 090305). United States Environmental Protection Agency; 2006. Available at: http://www.epa.gov/oppbppd1/biopesticides/ingredients//tech-- docs/brad-090305.pdf. Accessed July 8, 2009.
15. Agricultural Research Service collection of entomopathogenic fungal cultures. United States Department of Agriculture. Available at: http:// www.ars.usda.gov/is/np/systematics/fungibact.htm. Accessed July 8, 2009.
16. Insect Mycology and the USDA-ARS Collection of Entomorphogenic Fungal Cultures (ARSEF). Available at: http://arsef.fpsnl.cornell. edu/mycology/ARSEF- Culture-Collection.html. Accessed July 8, 2009.
17. Urtz BE, Rice WC. RAPD-PCR characterization of B. bassiana isolates from the rice water weevil Lissorhoptrus oryzophilus. Lett Appl Microbiol. 1997;25:405-409.
18. de Hoog GS. The genera Beauveria, Isaria, Tritirachium and Acrodontium gen nov. Studies in Mycology. 1972:1:1-41.
19. de Hoog GS, Guarro J, Gené J, et al. Atlas of Clinical Fungi. 2nd ed. Utrecht, The Netherlands: ASM Press; 2001:523-525.
20. Tucker DL, Beresford CH, Sigler L, et al. Disseminated B. bassiana infection in a patient with acute lymphoblastic leukemia. J Clin Microbiol. 2004;42:5412-5414.
21. Chang SD, Jun JH. A case of Beauveria bassiana keratitis confirmed by gene sequencing (PowerPoint Presentation given at the American Society of Cataract and Refractive Surgery 2008 meeting). Available at: http:// ascrs2008.abstractsnet.com/aoriginal.wcs?entryid=000122. Accessed July 8, 2009.
22. Jun KR, Jang MS, Park SJ, et al. A case of Beauveria bassiana Keratitis. Korean J Clin Microbio [Korean]. 2007;10:73-76.
23. Sonoyama H, Araki-Sasaki K, Kazama S, et al. The characteristics of keratomycosis by Beauveria bassiana and its successful treatment with antimycotic agents. Clin Ophthalmol. 2008;2:675-678.
24. Henke MO, De Hoog GS, Gross U, et al. Human deep tissue infection with an entomopathogenic Beauveria species. J Clin Microbiol. 2002;40: 2698-2702.
25. Gürcan, S, Tug? rul HM, Yörük Y, et al. First case report of empyema caused by B. bassiana. Mycoses. 2006;49:246-248.
26. Iyer SA, Tuli SS, Wagoner RC. Fungal keratitis: emerging trends and treatment outcomes. Eye Contact Lens. 2006;32:267-271.
27. Ide T, Miller D, Alfonso EC, et al. Impact of contact lens group on antifungal efficacy of multipurpose disinfecting contact lens solutions. Eye Contact Lens. 2008;34:151-159.
28. Bunya VY, Hammersmith KM, Rapuano CJ, et al. Topical and oral voriconazole in the treatment of fungal keratitis. Am J Ophthalmol. 2007; 143:151-153.
29. Jurkunas UV, Langston PD, Colby K. Use of voriconazole in the treatment of fungal keratitis. Int Ophthalmol Clin. 2007;47:47-59.
30. Giaconi JA, Maragon FB, Miller D, et al. Voriconazole and fungal keratitis: a report of two treatment failures. J Ocul Pharmacol Ther. 2006; 22:437-439.
31. Prakash G, Sharma N, Goel M, et al. Evaluation of intrastromal injection of voriconazole as a therapeutic adjunctive for the management of deep recalcitrant fungal keratitis. Am J Ophthalmol. 2008;146:56-59.
32. Thiel MA, Zinkernagel AS, Burhenne J, et al. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother. 2007;51:239-244.
33. Vemulakonda GA, Hariprasad SM, Mieler WF, et al. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol. 2008;126:18-22.
34. Lau D, Fedinands M, Leung L, et al. Penetration of voriconazole, 1%, eyedrops into human aqueous humor: a prospective open-label study. Arch Ophthalmol. 2008;126:343-346.
35. Medical interventions for fungal keratitis [review]. The Cochrane Collaboration. The Cochrane Library 2008, Issue 2.
36. Hariprasad SM, Mieler WF, Lin TK, et al. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol. 2008;92:871-878.